DE69732711D1 - Gamma-heregulin - Google Patents

Gamma-heregulin

Info

Publication number
DE69732711D1
DE69732711D1 DE69732711T DE69732711T DE69732711D1 DE 69732711 D1 DE69732711 D1 DE 69732711D1 DE 69732711 T DE69732711 T DE 69732711T DE 69732711 T DE69732711 T DE 69732711T DE 69732711 D1 DE69732711 D1 DE 69732711D1
Authority
DE
Germany
Prior art keywords
adhesins
chimeric
erbb2
heteromultimer
heteromultimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69732711T
Other languages
English (en)
Other versions
DE69732711T2 (de
Inventor
M Schaefer
Mark Sliwkowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE69732711D1 publication Critical patent/DE69732711D1/de
Application granted granted Critical
Publication of DE69732711T2 publication Critical patent/DE69732711T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/971—Capture of complex after antigen-antibody reaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE69732711T 1996-07-12 1997-07-08 Gamma-heregulin Expired - Lifetime DE69732711T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2164096P 1996-07-12 1996-07-12
US21640P 1996-07-12
PCT/US1997/011841 WO1998002541A1 (en) 1996-07-12 1997-07-08 Gamma-heregulin

Publications (2)

Publication Number Publication Date
DE69732711D1 true DE69732711D1 (de) 2005-04-14
DE69732711T2 DE69732711T2 (de) 2006-03-16

Family

ID=21805329

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69732711T Expired - Lifetime DE69732711T2 (de) 1996-07-12 1997-07-08 Gamma-heregulin

Country Status (8)

Country Link
US (6) US6096873A (de)
JP (2) JP4382879B2 (de)
AT (1) ATE290595T1 (de)
AU (1) AU727606B2 (de)
CA (1) CA2257839C (de)
DE (1) DE69732711T2 (de)
IL (4) IL127892A0 (de)
WO (1) WO1998002541A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
AU727606B2 (en) * 1996-07-12 2000-12-14 Genentech Inc. Gamma-heregulin
US20010023241A1 (en) 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
WO2000035474A1 (en) * 1998-12-11 2000-06-22 Khurana Tejvir S Neurite derived growth factors for use in the treatment of muscular dystrophy
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
JP4579471B2 (ja) * 1999-06-25 2010-11-10 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる前立腺癌の処置
EP2112167A3 (de) * 1999-06-25 2010-12-22 Genentech, Inc. Humanisierte ANTI-ERBB2-Antikörper und Behandlung mit ANTI-ERBB2-Antikörpern
HUP0301349A3 (en) * 1999-07-15 2005-12-28 Genetics Inst Llc Cambridge Formulations for il-11
ATE438411T1 (de) * 1999-08-27 2009-08-15 Genentech Inc Dosierung für die behandlung mit anti erbb2- antikörpern
ATE441433T1 (de) * 2000-05-19 2009-09-15 Genentech Inc Gennachweisverfahren zur verbesserung der wahrscheinlichkeit einer wirkungsvollen antwort auf eine krebstherapie mit einem erbb- antagonisten
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
WO2002055704A2 (en) * 2001-01-09 2002-07-18 Curagen Corp Proteins, polynucleotides encoding them and methods of using the same
CA2455830C (en) * 2001-07-31 2012-10-09 Wayne State University Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans
WO2003049693A2 (en) * 2001-12-06 2003-06-19 Wyeth Method and composition for inducing weight loss
AU2003230929A1 (en) * 2002-04-12 2003-10-27 Raven Biotechnologies, Inc. Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
AU2003295798B2 (en) * 2002-11-21 2009-09-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
ATE409484T1 (de) * 2002-12-17 2008-10-15 Centre Nat Rech Scient Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit
SE0301087D0 (sv) * 2003-04-14 2003-04-14 Cartela Ab New monoclonal antibody
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
EP1981525B1 (de) * 2005-12-30 2015-01-21 Zensun (Shanghai) Science and Technology Limited Verlängerte freisetzung von neuregulin für verbesserte herzfunktion
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
WO2008150485A2 (en) * 2007-05-29 2008-12-11 Wyeth Erbb2 binding proteins and use thereof
US8362215B2 (en) 2009-04-29 2013-01-29 Trellis Bioscience, Llc Antibodies immunoreactive with heregulin-coupled HER3
KR101186218B1 (ko) 2009-08-21 2012-10-08 경희대학교 산학협력단 히레귤린 베타1의 ｅｇｆ-성 도메인 펩타이드의 용도
NZ599499A (en) * 2009-10-14 2014-06-27 Acorda Therapeutics Inc Use of a neuregulin to treat peripheral nerve injury
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
US5283187A (en) * 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
EP0452364B1 (de) * 1988-12-22 2002-05-22 Genentech, Inc. Verfahren zur herstellung von wasserlöslichen polypeptiden
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
EP0479909B1 (de) 1989-06-29 1996-10-30 Medarex, Inc. Bispezifische reagenzien für die aids-therapie
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
EP0444961A1 (de) * 1990-03-02 1991-09-04 Bristol-Myers Squibb Company Her3: Ein neues EGF-Rezeptor Homologes
NO921040L (no) * 1991-03-17 1992-09-18 Yeda Res & Dev Stimulerende faktor for neu-reseptoren
US5716930A (en) * 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
GB9107566D0 (en) * 1991-04-10 1991-05-29 Ludwig Inst Cancer Res Glial mitogenic factors,their preparation and use
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
WO1993016178A2 (en) * 1992-02-12 1993-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sequences characteristic of human gene transcription product
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO1993022424A1 (en) * 1992-04-29 1993-11-11 Amgen Inc. RECOMBINANT STIMULATING FACTOR OF THE neu RECEPTOR
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
CA2145769A1 (en) * 1992-09-29 1994-04-14 Gerald D. Fischbach Trophic factor having ion channel-inducing activity in neuronal cells
CA2103323A1 (en) * 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
WO1994028133A1 (en) * 1993-05-21 1994-12-08 Amgen Inc. Recombinant neu differentiation factors
WO1995002052A1 (en) * 1993-07-06 1995-01-19 F. Hoffmann-La Roche Ag Mammamodulin, a hormone-independent mammary tumor cells specific protein
ES2116066T3 (es) 1993-11-23 1998-07-01 Genentech Inc Ensayo de activacion del receptor quinasa.
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5804396A (en) * 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU727606B2 (en) * 1996-07-12 2000-12-14 Genentech Inc. Gamma-heregulin

Also Published As

Publication number Publication date
IL191077A (en) 2011-12-29
US6096873A (en) 2000-08-01
JP4382879B2 (ja) 2009-12-16
IL127892A (en) 2008-08-07
WO1998002541A1 (en) 1998-01-22
ATE290595T1 (de) 2005-03-15
CA2257839C (en) 2012-10-23
IL191078A (en) 2011-12-29
US8226935B2 (en) 2012-07-24
AU727606B2 (en) 2000-12-14
CA2257839A1 (en) 1998-01-22
US6916624B2 (en) 2005-07-12
IL191077A0 (en) 2008-11-03
US20030078389A1 (en) 2003-04-24
US20090042797A1 (en) 2009-02-12
US7585673B2 (en) 2009-09-08
US20060029602A1 (en) 2006-02-09
IL191078A0 (en) 2008-11-03
JP2009235108A (ja) 2009-10-15
JP2000515740A (ja) 2000-11-28
US20100135957A1 (en) 2010-06-03
IL127892A0 (en) 1999-10-28
DE69732711T2 (de) 2006-03-16
US6500941B1 (en) 2002-12-31
AU3720897A (en) 1998-02-09

Similar Documents

Publication Publication Date Title
DE69732711D1 (de) Gamma-heregulin
ATE486937T1 (de) Chimärische heteromultimerische adhesine
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
NZ516258A (en) Tek antagonists
MX9604316A (es) Anticuerpos agonistas de la proteina tirosina cinasa.
DE69942753D1 (de) Peptidantagonist von Zonulin und dessen Verwendung
TR199902194T2 (xx) +p38 protein kinaz inhibit�rleri olarak ikameli azot ihtiva eden heterosikler.
DE69129990T2 (de) Modifizierter menschlicher tumornekrosisfaktor-alpha-rezeptor
MA32449B1 (fr) Agents de liaison de notch et antagonistes de notch ainsi que procedes d'utilisation correspondants
NZ337413A (en) Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer.
ATE412432T1 (de) Internalisierende erbb2 antikörper
EP0584082A4 (en) Domains of extracellular region of human platelet derived growth factor receptor polypeptides
DE69918946D1 (de) Rezeptoren für il-18
DE69128543D1 (de) Monoklonale antikörper der maus
DE69735502D1 (de) Mutanten des lag-3 proteins, ihre expression und verwendung
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
DE69333660D1 (de) Pct-65 serotonin rezeptor
AU2001245209A1 (en) Screening methods for bone morphogenetic mimetics
NZ336781A (en) Fibronectin binding protein compositions, antibodies thereto, and methods of use
AU2003288810A1 (en) Peptides that bind to the heparin binding domian of vegf and vegfr-2
MX9603045A (es) Antagonistas de los receptores endoteliales.
WO2001016181A3 (en) Crystal structures of domains of receptor protein tyrosine kinases and their ligands
WO2002076507A3 (en) Uses of opg ligand to modulate immune responses
EP1012313A4 (de) INTRAZELLULÄRE INHIBITOREN DER Gq-PROTEINSIGNALKETTE
DE59813016D1 (de) Cadherin derived growth factor und seine verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition